Denver, COLORADO1 Active Studies

Alpha-1 Antitrypsin Deficiency Clinical Trials in Denver, COLORADO

Find 1 actively recruiting alpha-1 antitrypsin deficiency clinical trials in Denver, COLORADO. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
185
Enrolling

Recruiting Alpha-1 Antitrypsin Deficiency Studies in Denver

About Alpha-1 Antitrypsin Deficiency Clinical Trials in Denver

Alpha-1 antitrypsin deficiency is a genetic condition that increases the risk of lung and liver disease due to low levels of the protective protein alpha-1 antitrypsin. It is one of the most common genetic causes of COPD. Treatment includes augmentation therapy and management of lung and liver symptoms.

There are currently 1 alpha-1 antitrypsin deficiency clinical trials recruiting participants in Denver, COLORADO. These studies are seeking a combined 185 participants. Research is being sponsored by Sanofi. Clinical trial participation is free and participants receive study-related medical care at no cost.

Alpha-1 Antitrypsin Deficiency Clinical Trials in Denver — FAQ

Are there alpha-1 antitrypsin deficiency clinical trials in Denver?

Yes, there are 1 alpha-1 antitrypsin deficiency clinical trials currently recruiting in Denver, COLORADO. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Denver?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Denver research site will contact you about next steps.

Are clinical trials in Denver free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Denver studies also compensate for your time and travel.

What alpha-1 antitrypsin deficiency treatments are being tested?

The 1 active trials in Denver are testing new therapies including novel drugs, biologics, and treatment approaches for alpha-1 antitrypsin deficiency.

Data updated March 2, 2026 from ClinicalTrials.gov